 <h1>Sevelamer Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to sevelamer: oral powder for suspension, oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, sevelamer may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking sevelamer:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Bloating</li>
<li>bloody, black, or tarry stools</li>
<li>constipation</li>
<li>diarrhea</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>heartburn</li>
<li>hives, itching, rash</li>
<li>hoarseness</li>
<li>indigestion</li>
<li>irritation</li>
<li>joint pain, stiffness, or swelling</li>
<li>nausea or vomiting</li>
<li>redness of the skin</li>
<li>stomach pain, cramping, burning, or tenderness</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>troubled breathing or swallowing</li>
<li>vomiting of material that looks like coffee grounds, severe and continuing</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of sevelamer may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>excess air or gas in the stomach or intestines</li>
<li>full feeling</li>
<li>passing gas</li>
<li>stomach discomfort or upset</li>
</ul><p>
<!-- end oral powder for suspension, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to sevelamer: oral capsule, oral powder for reconstitution, oral tablet</i></p><h3>General</h3><p>The most frequently occurring adverse reactions included nausea, vomiting, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal events are the most common adverse reactions reported with this drug.  Based on studies of 8 to 52 weeks, the most common reason for drug withdrawal are gastrointestinal adverse reactions (3% to 16%).<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, flatulence, constipation, gastrointestinal reflux disease</p>
<p><b>Frequency not reported</b>: Dysphagia, diverticulitis</p>
<p><b>Postmarketing reports</b>: Fecal impaction, ileus, intestinal obstruction, intestinal perforation<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Peritonitis<sup>[Ref]</sup></p><p>A clinical study in patients receiving peritoneal dialysis (n=143) found the most frequently occurring treatment emergent serious adverse reaction was peritonitis.  Peritonitis occurred in 8 patients receiving sevelamer and 2 patients on active control.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia</p>
<p><b>Uncommon</b> (0.1% to 1%): Acidosis, increased serum chloride levels, decreased carbon dioxide<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Hypersensitivity<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasopharyngitis, bronchitis</p>
<p><b>Common</b> (1% to 10%): Cough, upper respiratory tract infection, dyspnea<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Postmarketing reports</b>: Pruritus, rash<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Arteriovenous fistula site complication, arteriovenous fistula site hemorrhage, arteriovenous fistula thrombosis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, headache<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, fever<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, muscle spasms, extremity pain<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Renagel (sevelamer)." Genzyme Corporation, Cambridge, MA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Renvela (sevelamer)." Genzyme Corporation, Cambridge, MA. </p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about sevelamer</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>12 Reviews</li>
<li>Drug class: phosphate binders</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Sevelamer &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Renvela, Renagel</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +4 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hyperphosphatemia of Renal Failure</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to sevelamer: oral capsule, oral powder for reconstitution, oral tablet</i></p><h3>General</h3><p>The most frequently occurring adverse reactions included nausea, vomiting, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal events are the most common adverse reactions reported with this drug.  Based on studies of 8 to 52 weeks, the most common reason for drug withdrawal are gastrointestinal adverse reactions (3% to 16%).<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, flatulence, constipation, gastrointestinal reflux disease</p><p><b>Frequency not reported</b>: Dysphagia, diverticulitis</p><p><b>Postmarketing reports</b>: Fecal impaction, ileus, intestinal obstruction, intestinal perforation<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Peritonitis<sup>[Ref]</sup></p><p>A clinical study in patients receiving peritoneal dialysis (n=143) found the most frequently occurring treatment emergent serious adverse reaction was peritonitis.  Peritonitis occurred in 8 patients receiving sevelamer and 2 patients on active control.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia</p><p><b>Uncommon</b> (0.1% to 1%): Acidosis, increased serum chloride levels, decreased carbon dioxide<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Hypersensitivity<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasopharyngitis, bronchitis</p><p><b>Common</b> (1% to 10%): Cough, upper respiratory tract infection, dyspnea<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Postmarketing reports</b>: Pruritus, rash<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Arteriovenous fistula site complication, arteriovenous fistula site hemorrhage, arteriovenous fistula thrombosis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, headache<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, fever<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, muscle spasms, extremity pain<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Renagel (sevelamer)." Genzyme Corporation, Cambridge, MA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Renvela (sevelamer)." Genzyme Corporation, Cambridge, MA. </p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about sevelamer</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>12 Reviews</li>
<li>Drug class: phosphate binders</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Sevelamer &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +4 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hyperphosphatemia of Renal Failure</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>